TECKRO
9.11.2021 15:06:09 CET | Business Wire | Press release
Teckro, creator of the only clinical trial platform that facilitates collaboration between and among stakeholders, today announced the launch of the Totally Clinical: Trial Triumphs & Rad Trends podcast. The series provides a medium for diverse stakeholders in the clinical trial ecosystem to engage in conversation; inspiring new ways to design, deliver, and improve participation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005899/en/
To promote the new podcast series, Teckro worked with award-winning actor John C. McGinley. Known as Dr. Perry Cox in the hit television series Scrubs , McGinley stars in a video introducing Totally Clinical .
Totally Clinical episodes cover a variety of topics, ranging from field research perspectives and patient experiences, to drug development advances and technology trends. Gary Hughes, Teckro co-founder and CEO, kicks off the series by talking about operating for the greater good and what it means to be a mission-driven company in the 21st Century.
“Teckro is already the hub for effective communication; connecting stakeholders despite the complex, distributed, and often siloed nature of clinical trials,” says Hughes. “Now with the introduction of the Totally Clinical podcast, we are broadening our ambition to engage even more stakeholders in conversations; advancing clinical research and expanding awareness of clinical trials as an option for best possible care.”
Other topics include:
- Dr. Deborah Zajchowski, scientific director for the non-profit Clearity Foundation , discusses how targeted clinical trials based on tumor biomarkers can help increase survival rates for ovarian cancer.
- Dr. Brendan Buckley, Teckro Chief Medical Officer, explores trends in clinical trials –from mega trials to personalized medicine.
- Lydia Beaudette, manager of growth at LMC Manna Research , presents the research site viewpoint and ways to reduce the burden of technology on staff who are already stretched thin.
- Maria Milas takes us through the “day in the life” of a clinical research associate (CRA) and how the pandemic is driving change for the better.
- And Martin Lovell, a prostate cancer survivor, recounts how a chance reading of a newspaper article saved his life.
“Every initiative that gets people talking is a step forward,” says Dr. Zajchowski, “but the Totally Clinical podcast series is also a chance for non-profit organizations to reach other audiences. It allows us to engage in conversations that might accelerate research for treatments and drugs that improve outcomes and survival.”
The Totally Clinical: Trial Triumphs & Rad Trends podcast is available ad-free on Spotify , Apple , and Google . If you are interested in submitting a topic for consideration, contact us .
About Teckro
Recognized as one of the fastest growing clinical trial start-ups, Teckro transforms the study protocol into a hub of communication and collaboration. It’s a digital platform that connects all study stakeholders with the knowledge they need when they need it. Thousands of investigators and more than 23,000 sites around the world rely on Teckro to execute clinical trials. Teckro works with emerging biotech and global pharmaceutical organizations, including 12 out of the Top 20 companies. Teckro supports all therapeutic areas, all phases, and any trial format including traditional in-clinic, decentralized clinical trials, or a hybrid approach.
More Information
- Visit teckro.com
- Connect with Teckro on LinkedIn
- Follow @teckroofficial on Twitter and Instagram
- Like Teckro on Facebook
- Subscribe to the Teckro YouTube channel
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005899/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer27.10.2026 08:30:00 CET | Press release
Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 First EU approval of Enhertu in the curative-intent early breast cancer setting Third approval for Enhertu in the EU in four months Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for
Avanzanite Bioscience Expands UK Presence and Appoints Sarah O’Connell as Country Manager27.10.2026 08:00:00 CET | Press release
Avanzanite Bioscience B.V., a European pharmaceutical company focused on rare diseases, today announced the expansion of its United Kingdom (UK) presence and the appointment of Sarah O’Connell as UK Country Manager. The move strengthens Avanzanite’s long-term commitment to the UK and its ability to help eligible patients access innovative rare disease medicines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027035012/en/ Sarah O'Connell, Country Manager, UK, Avanzanite Bioscience “The UK is essential to our ambition of building Avanzanite into a European rare disease champion. We feel a deep and lasting connection to this market and there is no European reach without the UK,” said Adam Plich, co-founder and CEO, Avanzanite Bioscience. “At a time when parts of the life sciences sector are reassessing their investment and presence in the UK, we are choosing to commit and build for the long term. With Sarah’s extensive rare
LTM Secures Strategic Engagement with a Global Banking and Financial Services Firm27.10.2026 05:30:00 CET | Press release
LTM, the Business Creativity partner to the world's largest enterprises, has secured a strategic engagement with a large global banking and financial services firm, further strengthening its position as a trusted technology and transformation partner to leading financial institutions. This two-year engagement is already underway with an option to extend for an additional year and has a potential value of up to USD 100 million. The engagement reflects the continued expansion of LTM’s relationship with the client and its growing role in advancing strategic technology programmes and supporting supplier consolidation initiatives across the organization. Under the agreement, LTM will serve as a preferred partner driving the consolidation and delivery of strategic technology requirements across key wealth, personal banking, and global functions. The engagement will leverage LTM’s deep banking-domain expertise, engineering excellence, and global delivery capabilities to support the client’s t
DDN Selected to Modernize Research Data Infrastructure at UNSW Sydney26.10.2026 22:30:00 CET | Press release
DDN EXAScaler and Arcitecta Mediaflux will replace 11 legacy storage systems, simplifying access to research data while balancing performance and cost DDN, the global leader in AI and data intelligence solutions, today announced that UNSW Sydney has selected DDN to deliver a new research data storage environment as part of the university’s Research Data Experience (RDE) program. Working with Australian software company Arcitecta, DDN will combine its EXAScaler parallel file system with Arcitecta’s Mediaflux® data management platform to help researchers spend less time managing data and more time using it. Following an extensive 18-month evaluation, UNSW selected an integrated approach that will replace 11 legacy storage systems with a coordinated environment for high-performance storage and enterprise data management. The decision reflects a broader challenge facing research-intensive institutions: how to support rapidly expanding scientific datasets while simplifying infrastructure, i
Agent Assurance by TestMu AI Is Now Generally Available, Letting Teams Test What Their AI Agents Actually Change26.10.2026 16:15:00 CET | Press release
The trial includes 4,000 credits and four concurrent runs, so a team can generate functional and adversarial suites from its own agent's docs and endpoint, with code optional, and gate CI on evidence-backed verdicts without booking a demo. TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, today announced the general availability of Agent Assurance. Agent Assurance tests AI agents that take actions, such as calling tools, writing files, and changing records, by checking what a run actually changed rather than what the agent says it did. Any team can now create a TestMu AI account and run it against its own agent without booking a demo first. Agent Assurance launched on August 17, 2026, behind a waitlist and a guided onboarding session. Since then, Rook, the CLI that runs Agent Assurance, has shipped a steady run of releases, shaped by feedback from early teams. Agent evaluation has mostly graded the final reply, and that reply can be wro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom